Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

  • End date
    Jul 23, 2024
  • participants needed
  • sponsor
    Fudan University
Updated on 23 January 2021
growth factor
tumor cells
epidermal growth factor receptor
triple negative breast cancer
progesterone receptor
epidermal growth factor
estrogen receptor
invasive breast cancer
adjuvant chemotherapy
chromogenic in situ hybridization


This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC4-T4) verses 6 cycles of weekly paclitaxel combined with carboplatin (PCb*6) in the adjuvant chemotherapy of non-triple negative breast cancer patients. The study is divided in to 2 branches: PANSY-1 and PANSY-2. PANSY-1 is a study of hormone receptor (HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative patients with 4 positive lymph node, while PANSY-2 is a study of HER2-positive patients with 1 positive lymph node.


PANSY-1 will be comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC-T) verses six cycles of paclitaxel combined with carboplatin (PCb).

PANSY-2 will be comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel with trastuzumab (EC-TH) verses six cycles of paclitaxel combined with carboplatin and trastuzumab (PCbH); both followed by 1 year adjuvant trastuzumab.

After pertuzumab became legally available in China, participants of PANSY-2 may choose to receive trastuzumab and pertuzumab dual targeted therapy, thus comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel with trastuzumab and pertuzumab (EC-THP) verses six cycles of paclitaxel combined with carboplatin, trastuzumab and pertuzumab (PCbHP); both followed by 1 year adjuvant trastuzumab and pertuzumab.

With the inclusion of pertuzumab in China's medical insurance in January 2020, study protocols were revised to include dual targeted therapy for HER2-positive participants.

Condition Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast
Treatment cyclophosphamide, docetaxel, carboplatin, Epirubicin, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab (qw), Trastuzumab (q3w)
Clinical Study IdentifierNCT04193059
SponsorFudan University
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Are you female?
Do you have Breast Cancer?
Do you have any of these conditions: Breast Cancer or cancer, breast or Breast Cancer Diagnosis or breast carcinoma?
Female patients aged 18-70 years old
Histologically confirmed unilateral invasive breast cancer (regardless of pathological type)
Operable breast cancer at first diagnosis, without any absolute surgical contraindication
No gross nor microscopic residual tumor after surgery
HER2-positive with 1 positive axillary lymph node; or estrogen receptor (ER) and/or progesterone receptor (PR)-positive and HER2-negative with 4 positive axillary lymph node. HER2-positive is defined as an immunohistochemistry (IHC) status of 3+, or a positive in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH)) test. ER-positive is defined as immunohistochemistry showing that 1% of tumor cells were ER positive. PR-positive is defined as immunohistochemistry showing that 1% of tumor cells were PR positive
Preoperative examination found no evidence of metastasis in clinical examination nor imaging examination
No peripheral neuropathy
Karnofsky score > 70\
Good postoperative recovery, at least 1 week has passed since most recent surgery
Has adequate bone marrow function: leukocyte count > 4x109 / L, absolute neutrophil count > 2x109 /L; platelet count > 100x109 /L, hemoglobin > 9g/dL
Has adequate liver function: alanine aminotransferase (ALT) < 1.5upper limit of normal (ULN), aspartate aminotransferase (AST) < 1.5ULN, alkaline phosphatase (AKP) < 2.5ULN, total bilirubin (TBIL) < 1.5ULN
Has adequate kidney function: serum creatinine < 1.5ULN
Contraception during treatment for women of childbearing age
Has adequate cardiac function: echocardiography showed left ventricular ejection fraction (LVEF) > 50%
Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up

Exclusion Criteria

Has received previous chemotherapy for late stage disease
Has bilateral breast cancer or bilateral carcinoma in situ
Has metastatic (Stage 4) breast cancer
Has clinical T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer)
Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy)
Has previous history of additional malignancy(with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ), including contralateral breast cancer
Is already participating in another clinical trial
Has severe systemic disease and/or uncontrolled infection
Has insufficient cardiac function: echocardiography showed LVEF< 50%
Has suffered from severe cardiovascular and cerebrovascular diseases disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure>150/90 mmHg, myocardial infarction, or cerebrovascular accident
Has known allergy to chemotherapy drugs used in this study
Is pregnant, is breast feeding, or is a woman of childbearing age who cannot practice effective contraceptives during treatment and until 8 weeks after the end of treatment
Has entered the study, but pre-treatment examination showed a positive pregnancy test
Has a history of mental disorders, cognitive impairment, inability to understand the study protocol and side effects, inability to complete the study protocol and follow-up workers (systematic evaluation is required before the patient is enrolled into the study), or is without independent civil capacity
The researchers judged patients to be unsuitable for the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note